{
    "clinical_study": {
        "@rank": "58721", 
        "acronym": "VANISH", 
        "arm_group": [
            {
                "arm_group_label": "Valsartan", 
                "arm_group_type": "Active Comparator", 
                "description": "During active run-in, all subjects will be started on valsartan at an initial dose of 40 mg twice daily (20 mg twice daily in children \u226416 years old, or adults with baseline systolic BP<100 mmHg).  This initial dose will be received through the mail within 2 weeks of Visit 1 and titration will begin after communication with the study coordinator confirming that trial eligibility criteria were met.  Valsartan dose will be titrated at 2-week intervals to a target dose of 320 mg/day in adults; 160 mg/day in children \u226535 kg; 80 mg/day in children <35 kg.\nSubjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group.  Treatment will continue for 2 years."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "During active run-in, all subjects will be started on valsartan at an initial dose of 40 mg twice daily (20 mg twice daily in children \u226416 years old, or adults with baseline systolic BP<100 mmHg).  This initial dose will be received through the mail within 2 weeks of Visit 1 and titration will begin after communication with the study coordinator confirming that trial eligibility criteria were met.  Valsartan dose will be titrated at 2-week intervals to a target dose of 320 mg/day in adults; 160 mg/day in children \u226535 kg; 80 mg/day in children <35 kg.\nSubjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group.  Treatment will continue for 2 years."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine whether treatment with valsartan will have\n      beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that\n      reflect myocardial structure, function and biochemistry."
        }, 
        "brief_title": "Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertrophic Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Hypertrophic", 
                "Hypertrophy", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, double-blind, placebo-controlled Phase II, randomized clinical trial\n      to assess the safety and efficacy of valsartan in attenuating disease evolution in early\n      HCM.  Sarcomere mutation carriers with asymptomatic or mildly symptomatic overt disease\n      (NYHA class I-II), and mutation carriers without left ventricular hypertrophy (LVH) will be\n      studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All subjects must have a Pathogenic or Likely Pathogenic HCM Sarcomere Mutation\n\n          -  The following categories of mutations are considered acceptable for subjects who have\n             previously undergone clinical genetic testing.  If results are ambiguous, they will\n             be reviewed by the Clinical Coordinating Center to determine eligibility.\n\n               1. Laboratory for Molecular Medicine (Pathogenic, Likely Pathogenic)\n\n               2. Transgenomics/ PGXHealth (Class I)\n\n               3. GeneDx (Disease causing; Variant; likely disease-causing; Published,\n                  disease-causing mutation; Novel, likely disease-causing, mutation)\n\n               4. Correlagen (Associated; Probably Associated\n\n        Overt HCM Cohort\n\n          -  LV wall thickness \u226512 mm and < 20 mm (in subjects \u226518 years) or z score \u22653 and < 10\n             as determined by rapid assessment by the echocardiographic core laboratory\n\n          -  NYHA functional class I or II; no perceived or only slight limitations in physical\n             activities\n\n          -  No resting or provokable LV obstruction (peak gradient \u2264 30 mmHg) on\n             clinically-obtained Exercise Tolerance Test (ETT)-echo within the past 24 months or\n             transthoracic echo with Valsalva maneuver within the past 12 months\n\n          -  Age 8-30 years\n\n          -  Able to attend follow-up appointments, complete all study assessments, and provide\n             written informed consent\n\n        Preclinical HCM Cohort (G+/LVH-)\n\n          -  LV Wall Thickness <12 mm (in subjects \u226518 years) or z score <3 (in subjects <18\n             years), as determined by rapid assessment by the echocardiographic core laboratory\n\n          -  Age 10-25 years\n\n          -  E' z score \u2264 -2 OR  ECG abnormalities other than Non-specific ST or T-wave\n             abnormalities (NSSTW) changes (Q waves, T wave inversion, repolarization changes)\n\n          -  Able to attend follow-up appointments, complete all study assessments, and provide\n             written informed consent\n\n        Subject Exclusion Criteria\n\n          -  Contraindication to angiotensin receptor blocker (ARB) administration, including\n             impaired renal function, hyperkalemia (serum K>5.0 mmol/L), prior history of\n             angioedema\n\n          -  Medical conditions associated with increased collagen turnover that may confound\n             interpretation of biomarkers of collagen synthesis (liver, pulmonary or renal\n             fibrosis, inflammatory states, cancer, trauma or surgery within 6 months of\n             enrollment)\n\n          -  Concomitant or prior use of ARB or ACE-inhibitors\n\n          -  Pregnant or breastfeeding females\n\n          -  Females of childbearing potential with no effective contraceptive method (including\n             abstinence)\n\n          -  Systemic Hypertension (HTN) (Systolic Blood Pressure (SBP) >140 and/or Diastolic\n             Blood Pressure (DBP) >90), or on medical therapy for HTN\n\n          -  Obstructive physiology, defined by resting, Valsalva-provoked or exercise-induced\n             gradient >30 mm Hg within the past 24 months\n\n          -  Prior septal myectomy or alcohol septal ablation\n\n          -  Known, suspected, or symptomatic coronary artery disease or evidence of prior\n             myocardial infarction based on symptoms or cardiac imaging\n\n          -  More than mild valvular heart disease or congenital heart disease (allowable\n             conditions include bicuspid aortic valve without stenosis or regurgitation;\n             spontaneously closed ventricular septal defects; patent foramen ovale, small\n             (</=2mm) restrictive ventricular septal defects with normal ventricular size, and\n             other minor defects that are considered allowable after review and consensus by the\n             echo core lab, participating pediatric cardiologists, and overall study PI)\n\n          -  Left ventricular ejection fraction (LVEF) <55%\n\n          -  Concomitant medical conditions that would preclude performance of or confound\n             interpretation of echocardiography, exercise testing, or CMR (eg, renal\n             insufficiency, lung disease, orthopedic/rheumatologic conditions, implantable\n             cardioverter-defibrillator (ICD) or pacemaker, atrial fibrillation)\n\n          -  Prior treatment or hospitalization for symptomatic heart failure\n\n          -  Participation in a clinical trial (except observational studies) involving\n             investigational medications within the previous 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912534", 
            "org_study_id": "VANISH", 
            "secondary_id": "5P50HL112349"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Valsartan", 
                    "Placebo"
                ], 
                "description": "40, 80 and 160 mg tablets of Valsartan", 
                "intervention_name": "Valsartan", 
                "intervention_type": "Drug", 
                "other_name": "Diovan"
            }, 
            {
                "arm_group_label": [
                    "Valsartan", 
                    "Placebo"
                ], 
                "description": "During Active Run-In, all patients take Valsartan.  During maintenance, all patients are randomized to valsartan or placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo pills manufactured to match Valsartan 160 mg, 80 mg, 40 mg tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Valsartan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Sarcomere Mutations", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "euan@stanford.edu", 
                    "last_name": "Euan Ashley, MD, PhD", 
                    "phone": "650-498-4900"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "investigator": {
                    "last_name": "Euan Ashley, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "matthew.taylor@ucdenver.edu", 
                    "last_name": "Matthew Taylor, MD, PhD", 
                    "phone": "303-724-1400"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado"
                }, 
                "investigator": [
                    {
                        "last_name": "Matthew Taylor, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Luisa Mestroni, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "emcnally@uchicago.edu", 
                    "last_name": "Elizabeth McNally, MD", 
                    "phone": "773-702-2672"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Elizabeth McNally, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "murphy@jhmi.edu", 
                    "last_name": "Anne Murphy, MD", 
                    "phone": "410-955-5987"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": [
                    {
                        "last_name": "Anne Murphy, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ted Abraham, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cho@partners.org", 
                    "last_name": "Carolyn Ho, MD", 
                    "phone": "617-732-5685"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham & Women's Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Carolyn Ho, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mark A. Fifer, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "colan@alum.mit.edu", 
                    "last_name": "Steven Colan, MD", 
                    "phone": "617-355-7893"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Children's Hospital Boston"
                }, 
                "investigator": [
                    {
                        "last_name": "Steven Colan, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Renee Margosian, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sday@umich.edu", 
                    "last_name": "Sharlene Day, MD", 
                    "phone": "734-615-7917"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan"
                }, 
                "investigator": [
                    {
                        "last_name": "Sharlene Day, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mark Russell, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "canter@kids.wustl.edu", 
                    "last_name": "Charles Canter, MD", 
                    "phone": "314-454-6095"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School Medicine"
                }, 
                "investigator": [
                    {
                        "last_name": "Charles Canter, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Keith Mankovitz, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jeffrey.towbin@cchmc.org", 
                    "last_name": "Jeffrey Towbin, MD", 
                    "phone": "513-636-3049"
                }, 
                "facility": {
                    "address": {
                        "city": "Cinncinati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cinncinnati Children's Hospital Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jeffrey Towbin, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "John Lynn Jeffries, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "leverh@ccf.org", 
                    "last_name": "Harry Lever, MD", 
                    "phone": "216-444-6970"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "investigator": [
                    {
                        "last_name": "Harry Lever, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kenneth Zahka, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.g.disalvo@vanderbilt.edu", 
                    "last_name": "Thomas DiSalvo, MD", 
                    "phone": "615-322-2318"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "investigator": [
                    {
                        "last_name": "Thomas DiSalvo, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jason Becker, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Larry Markham, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lee.benson@sickkids.ca", 
                    "last_name": "Lee Benson, MD", 
                    "phone": "416-813-6141"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G1X8"
                    }, 
                    "name": "Toronto Sick Kids"
                }, 
                "investigator": {
                    "last_name": "Lee Benson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "harry.rakowski@uhn.ca", 
                    "last_name": "Harry Rakowski, MD", 
                    "phone": "416-340-4062"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4W3S5"
                    }, 
                    "name": "Toronto General Hospital"
                }, 
                "investigator": {
                    "last_name": "Harry Rakowski, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM", 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Carolyn Y. Ho, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Myocardial injury, hemodynamic stress, collagen metabolism, functional capacity, myocardial fibrosis, cardiac morphology, and cardiac function endpoints will be combined into a single composite z-score.", 
            "measure": "A combined single composite z-score (described below) will serve as primary surrogate endpoint to monitor response to valsartan treatment", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912534"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Improvement in, stability of, or attenuation of progression in 7 components of primary composite outcomes; left atrial size; assessment of left ventricle (LV) mass by cardiac magnetic resonance imaging(CMR); LV systolic and diastolic function; the degree of interstitial myocardial fibrosis as assessed by novel CMR sequences; additional parameters from metabolic exercise testing and additional serum biomarkers that reflect fibrosis, injury and stress", 
                "measure": "Impact of valsartan treatment on disease pathology", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Specifically, decline 1 point on NYHA or increase in therapy for HCM; development of arrhythmias; time to development of HCM-related symptoms; development of obstructive physiology; development of a new murmur; activity level as tracked by activity monitor and survey.", 
                "measure": "Clinical outcomes and assessment of symptom burden", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Incidence of adverse drug reactions, frequency of subject drop-out, and responses to validated quality of life metrics between valsartan and placebo-treated group", 
                "measure": "Incidence of adverse drug reactions, frequency of subject drop-out, and responses to validated quality of life metrics between valsartan and placebo-treated group", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "New England Research Institutes", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "New England Research Institutes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}